YB1-mRNA / HKND YB1 Pharma - LARVOL DELTA

Immunohistochemical analysis of YB-1 expression in the developing mouse eye. (PubMed, Eur J Histochem) - "YB-1 mRNA could be detected by RT-PCR and sequencing the PCR product in retinal tissue of adult mice...Expression of the YB-1 protein was detected in all retinal cells, as well as in the corneal and lens epithelial cells, throughout all stages of eye development examined. These findings suggest that YB-1 could have a significant role in the eye, potentially related to development and differentiation."

Journal • Preclinical • Oncology

Autoregulation of YB-1 Synthesis in Cells. (PubMed, Biochemistry (Mosc)) - "Experiments with reporter constructs showed that both UTRs of the YB-1 mRNA are involved in autoregulation, thus resolving the contradiction in the literature. These results highlight a sophisticated mechanism for controlling YB-1 levels, which requires both 5' and 3' UTRs of the YB-1 mRNA, and confirm their role in fine-tuning YB-1 synthesis."

Journal • YBX1

Targeting YBX1: A novel therapeutic strategy for gastric cancer through regulation of cellular senescence and mTOR signaling. (PubMed, Tissue Cell) - "YBX1 mRNA and protein levels were significantly higher in GC tissues than in adjacent normal tissues (P < 0.001), and high expression was associated with reduced overall survival (P < 0.05)...Thus, this study underscores YBX1 as a pivotal regulator of GC cell proliferation, senescence, and survival, offering a promising avenue for targeted therapies. By leveraging YBX1 inhibition, this work lays a foundation for developing precision medicine approaches in GC treatment."

Journal • Gastric Cancer • Oncology • Solid Tumor • EIF4EBP1 • YBX1

Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. (PubMed, Sci Rep) - "Increased YB-1-mRNA expression was detected in basal/squamous subtype in TCGA BLCA cohort compared to urothelial and luminal BLCA and correlated with patient outcomes...In a novel in ovo xenograft model, XVir-N-31 impaired growth of xenografts of patient-derived ex vivo cell lines (p-SCC, p-UC) with growth suppression rates of 39-49%. We provide preclinical evidence ex vivo and in ovo for high efficacy of XVir-N-31 based oncolytic virotherapy as novel SCC therapy."

Journal • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • YBX1

Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer. (PubMed, Sci Rep) - "YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CCNA1 • YBX1